Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ...

JMP Securities analyst Silvan Tuerkcan has reiterated their bullish stance on VOR stock, giving a Buy rating on November 8. Silvan ...

While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are ...

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...

Keywords: hematological malignancy, metabolism microenvironment, immune microenvironment, tumor-microenvironment crosstalk Important Note: All contributions to this Research Topic must be within the ...

A disease historically associated with malnourishment on sailing vessels may have a new, modern culprit: Bariatric surgery.

Anna Lindstrand at the research group Rare Diseases receives SEK 1.200.000 for the project "Resolving Structural Variant Complexity in Hematological Malignancies". Ann Nordgren at the research group ...

Induction chemotherapy shows significant improvements for survival in patients with locally advanced cervical cancer.

Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a ...

HC Wainwright reaffirmed their buy rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research note issued to investors on Friday,Benzinga reports. The firm currently has a $17.50 price ...